Plus   Neg

Arrowhead Pharmaceuticals Inc. (ARWR) Has Risen To A New High On Study Data

Arrowhead Pharmaceuticals Inc. (ARWR) announced Thursday morning that it will present clinical data for ARO-HBV at the 18th World Gastroenterologists Summit in Auckland, New Zealand. The results showed a reduction in circulating HBV surface antigen.

Arrowhead Pharmaceuticals gapped open sharply higher Thursday morning and is now up 5.05 at $19.15 on above average volume. The stock has broken out to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT